---
title: "BioNTech SE (BNTX.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/BNTX.US.md"
symbol: "BNTX.US"
name: "BioNTech SE"
industry: "Biotechnology"
datetime: "2026-03-15T22:48:53.333Z"
locales:
  - [en](https://longbridge.com/en/quote/BNTX.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/BNTX.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/BNTX.US.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/BNTX.US.md) | [繁體中文](https://longbridge.com/zh-HK/quote/BNTX.US.md)


# BioNTech SE (BNTX.US)

## Company Overview

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.biontech.de](https://www.biontech.de) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-03-15T04:30:13.000Z

**Overall: C (0.50)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 67 / 402 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 11.71% |  |
| Net Profit YoY | -82.86% |  |
| P/B Ratio | 0.97 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 21882937616.76 |  |
| Revenue | 3306743442.56 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -5.88% | D |
| Profit Margin | -39.59% | E |
| Gross Margin | 78.70% | A |
| Revenue YoY | 11.71% | B |
| Net Profit YoY | -82.86% | E |
| Total Assets YoY | 10.21% | B |
| Net Assets YoY | 11.83% | B |
| Cash Flow Margin | -252.61% | D |
| OCF YoY | 11.71% | B |
| Turnover | 0.13 | D |
| Gearing Ratio | 12.57% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - BioNTech SE",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "11.71%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-82.86%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.97",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "21882937616.76",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "3306743442.56",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-5.88%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-39.59%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "78.70%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "11.71%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "-82.86%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "10.21%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "11.83%",
          "rating": "B"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-252.61%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "11.71%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.13",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "12.57%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -16.72 | 491/402 | - | - | - |
| PB | 0.97 | 83/402 | 1.26 | 1.17 | 1.09 |
| PS (TTM) | 6.62 | 133/402 | 8.51 | 7.83 | 7.14 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Stoke Therapeutics (STOK.US) | A | A | B | A | B | A |
| 03 | MiMedx (MDXG.US) | A | B | A | B | B | A |
| 04 | Rigel Pharma (RIGL.US) | A | A | B | B | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-03-13T04:00:00.000Z

Total Analysts: **19**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 13 | 68% |
| Overweight | 1 | 5% |
| Hold | 5 | 26% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 91.19 |
| Highest Target | 175.89 |
| Lowest Target | 102.99 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/BNTX.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/BNTX.US/norm.md)
- [Related News](https://longbridge.com/en/quote/BNTX.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/BNTX.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**